Navigation Links
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Date:5/14/2008

ancing from leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all of which have built some of the world's leading life sciences companies, and additional investors. The company's board of directors includes Amir Nashat, general partner, Polaris Venture Partners; Robert Nelsen, co-founder and managing director, ARCH Venture Partners; and Bryan Roberts, managing general partner, Venrock. Nelsen and Roberts were named to the Forbes 2008 Midas List of the top 100 tech deal makers in the world.

"Fate has brought together the best minds in science with the top business minds in biotech," said Alex Rives, founding president of Fate. "Paul Grayson and John Mendlein are respected biotechnology executives with a history of developing breakthrough pharmaceuticals and innovative business strategies. Their leadership is the next step in creating an entirely new therapeutic paradigm for non-embryonic or adult stem cell medicine."

About Fate Therapeutics

Fate Therapeutics is a privately held biopharmaceutical company pioneering the field of renewal therapies, a newly emerging area of research and drug development. Founded by a world-class collaborative team of luminaries in the science of adult stem cell biology, management with a proven track record in translating new science into innovative drug and business opportunities, and an investor syndicate with an unparalleled history of establishing and advancing revolutionary biotechnology companies, Fate is working to launch a new era of medicine with the potential to offer new hope to patients afflicted with some of the most difficult to treat conditions, including degenerative diseases such as diabetes, Parkinson's and Alzheimer's Disease, ALS, heart failure, stroke and paralysis; developmental disorders including Down syndrome; and metastatic cancers.

For more information, see http://www.fatetherapeutic
'/>"/>

SOURCE Fate Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
9. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 2014 Deep Research Report on ... and in-depth research report on the China Linalool ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... , NEW YORK , May 19 After ... 12 former Novartis sales reps $3.36 million in compensatory ... stronger dose of the same medicine.  Announcing the amount of punitive ... an additional $250 million for the gender discrimination it ...
... May 19 Volcano Corporation (Nasdaq: VOLC ... CE Mark approval for its PrimeWire PRESTIGE™ Pressure Guide ... and multi-vessel disease. This next generation pressure wire is ... and stand-alone physiology systems as well as various hemodynamic ...
... ,, ATLANTA , May 19 ... partnership to adapt the Sivix key computing fob and ... sensing safety solutions.  These solutions are based upon the ... sensing unit inside the helmet of an athlete, firefighter, ...
Cached Biology Technology:Novartis Class Awarded $250 Million in Punitive Damages 2Novartis Class Awarded $250 Million in Punitive Damages 3Novartis Class Awarded $250 Million in Punitive Damages 4Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 2Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 3Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 4Volcano Announces 510(k) Clearance, CE Mark Approval, and First Clinical Use for the PrimeWire PRESTIGE(TM) Pressure Guide Wire 5Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... Genetic factors in African Americans with chronic kidney disease ... renal disease (ESRD) compared to white Americans, according to ... England Journal of Medicine . Researchers at Johns Hopkins ... two separate studies: the African American Study of Kidney ...
... shape or move with no power source other than ... led by the University of Pittsburgh. The researchers are ... converting light energy into mechanical work and potentially eliminating ... and power sources. "I like to compare this ...
... large family of cell-surface receptors that respond to ... factors such as epidermal growth factor (EGF) and ... neuronal guidance. Ligand binding stimulates the tyrosine kinase ... enzymes and adapter proteins that activate intracellular signaling ...
Cached Biology News:Gene puts African-Americans at higher risk for kidney failure 2Snap to attention: Polymers that react and move to light 2
... easy transformation of the budding yeast, Saccharoyces ... simply by mixing a plasmid DNA and ... No complicated steps, such as centrifugation or ... particularly well suited for high-throughput transformation of ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
Biology Products: